MET and hepatocellular carcinoma: Extending from the phase II data, there are currently two phase III double-blind, randomised controlled trials that are recruiting patients with advanced HCC and high c-MET-expression to compare tivantinib as second-line treatment against placebo, namely the METIV-HCC trial in the West (ClinicalTrials.gov Identifier: NCT01755767) and the JET-HCC trial in Japan (ClinicalTrials.gov Identifier: NCT02029157).